NC
YARW

Nexthera Capital’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Nexthera Capital’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-21
Closed -$2.79M – 54
2018
Q1 		$2.79M Buy
+21
New +$2.55M 0.46% 38

Other funds holding YARW

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Nexthera Capital's YARW Position: Q2 2018 in Review

Nexthera Capital sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q2 2018, closing a stake of 21 shares — an estimated $2.79M sold.

Nexthera Capital first reported a position in YARW in Q1 2018 and held it in 1 quarter. The position peaked at $2.79M in Q1 2018. 35 funds tracked by Wall St. Rank hold YARW as of Q2 2018.

  • Nexthera Capital reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Nexthera Capital sold 21 Yarrow Bioscience, Inc. Common Stock shares in Q2 2018, an estimated $2.79M.
  • Nexthera Capital first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • Nexthera Capital's Yarrow Bioscience, Inc. Common Stock position peaked at $2.79M in Q1 2018.
  • 35 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q2 2018.

Based on Nexthera Capital's 13F filing for Q2 2018, filed 14 Aug 2018.